Seeking Alpha

Leerink Swann weighs in on Questcor Pharmaceuticals (QCOR +9.6%) after Medicaid's bump-up in...

Leerink Swann weighs in on Questcor Pharmaceuticals (QCOR +9.6%) after Medicaid's bump-up in reimbursement rates, upping its revenue projection on the company to $675M from $626M and its EPS estimates from $3.67 to $4.21.
From other sites
Comments (1)
  • drdon
    , contributor
    Comments (202) | Send Message
     
    Today's action and market reaction bodes well for QCOR and all of us who stayed strong long throughout the recent bout with the shorts. There is and will continue to be a short squeeze as a background to a well positioned company with an impeccable corporate model.
    4 Sep 2012, 04:46 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs